arrow
K

Kun-Ho Yoon

Seoul St. Mary's Hospital
H指数:65
被引数:2.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Lobeglitazone improves glycaemic control as add-on therapy to empagliflozin plus metformin in patients with type 2 diabetes mellitus: A double-blind, randomised, placebo-controlled trial

Lobeglitazone作为empagliflozin联合metformin的附加疗法,可改善2型糖尿病患者的血糖控制:一项双盲、随机、安慰剂对照试验

2025-11-140
OAAI
Efficacy and safety of lobeglitazone added to metformin and sitagliptin combination therapy in patients with type 2 diabetes: A 52-week, multicentre, randomized, placebo-controlled, phase III clinical trial

洛格列酮添加到二甲双胍和西格列汀联合治疗中的有效性和安全性:一项52周、多中心、随机、安慰剂对照、III期临床试验

2025-07-290
OAAI
A 52-week efficacy and safety study of enavogliflozin versus dapagliflozin as an add-on to metformin in patients with type 2 diabetes mellitus: ENHANCE-M extension study

enavogliflozin与dapagliflozin作为2型糖尿病患者二甲双胍的52周疗效和安全性研究: 增强-M扩展研究

2024-03-080
OA
Efficacy and Safety of Evogliptin Add-on Therapy to Dapagliflozin/Metformin Combinations in Patients with Poorly Controlled Type 2 Diabetes Mellitus: A 24-Week Multicenter Randomized Placebo-Controlled Parallel-Design Phase-3 Trial with a 28-Week Extension
2023-11-301
OAAI
Gender-associated cardiometabolic risk profiles and health behaviors in patients with type 2 diabetes: a cross-sectional analysis of the Joint Asia Diabetes Evaluation (JADE) program
2023-03-013
OAAI